Display options
Cite
El-Sisi AE, Hegazy SK, Metwally SS, et al. Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2011;2(4):155-64doi: 10.1177/2042018811415985.
El-Sisi, A. E., Hegazy, S. K., Metwally, S. S., Wafa, A. M., & Dawood, N. A. (2011). Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes. Therapeutic advances in endocrinology and metabolism, 2(4), 155-64. https://doi.org/10.1177/2042018811415985
El-Sisi, Alaa E, et al. "Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes." Therapeutic advances in endocrinology and metabolism vol. 2,4 (2011): 155-64. doi: https://doi.org/10.1177/2042018811415985
El-Sisi AE, Hegazy SK, Metwally SS, Wafa AM, Dawood NA. Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2011 Aug;2(4):155-64. doi: 10.1177/2042018811415985. PMID: 23148181; PMCID: PMC3474636.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Endocrinol Metab. 2011 Aug;2(4):155-64. doi: 10.1177/2042018811415985.

Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes.

Therapeutic advances in endocrinology and metabolism

Alaa E El-Sisi, Sahar K Hegazy, Shereen S Metwally, Alaa M Wafa, Naglaa A Dawood

Affiliations

  1. Faculty of Pharmacy, Tanta University, Egypt.

PMID: 23148181 PMCID: PMC3474636 DOI: 10.1177/2042018811415985

Abstract

OBJECTIVE: This study investigated the possibility that genetic factors, such as polymorphism of K inward rectifier subunit (Kir6.2), E23K, and Arg(972) polymorphism of insulin receptor sub-strate-1 (IRS-1), may predispose patients to sulfonylurea failure.

METHODS: A total of 100 unrelated Egyptian patients with type 2 diabetes were recruited. They were divided into two equal groups: group I consisted of patients with secondary failure to sulfonylurea (hemoglobin A(1c) ≥ 8% despite sulfonylurea therapy) while group II consisted of patients whose condition was controlled with oral therapy.

RESULTS: Of all the patients, 45% and 14% were carriers of the K allele and Arg(972) variants respectively. The frequency of the K allele was 34% among patients with diabetes that was controlled with oral therapy and 56% among patients with secondary failure to sulfonylurea. The frequency of the Arg(972) IRS-1 variant was 6% among patients with diabetes controlled with oral therapy and 22% among patients with secondary failure.

CONCLUSION: The E23K variant of the Kir6.2 gene and Arg(972) IRS-1 variants are associated with increased risk for secondary failure to sulfonylurea.

Keywords: Arg972 IRS-1 variant; E23K polymorphism; IRS-1; KCNJ11; Kir6.2; sulfonylurea failure

References

  1. FASEB J. 2001 Jan;15(1):22-24 - PubMed
  2. Diabetes. 1996 Feb;45(2):267-9 - PubMed
  3. Diabetes. 1997 Nov;46(11):1743-8 - PubMed
  4. J Clin Invest. 1998 Apr 15;101(8):1784-8 - PubMed
  5. Diabetologia. 2001 Mar;44(3):367-72 - PubMed
  6. Diabetes. 2003 Mar;52(3):887-90 - PubMed
  7. Diabetes. 2002 Sep;51(9):2854-60 - PubMed
  8. Clin Chem. 1974 Apr;20(4):470-5 - PubMed
  9. Diabetes. 1997 Jul;46(7):1227-9 - PubMed
  10. Clin Chem. 1982 Oct;28(10):2077-80 - PubMed
  11. Diabetes. 2002 May;51(5):1419-24 - PubMed
  12. N Engl J Med. 2004 Apr 29;350(18):1838-49 - PubMed
  13. BMC Med Genet. 2006 Apr 07;7:36 - PubMed
  14. Exp Clin Endocrinol Diabetes. 1999;107(5):318-22 - PubMed
  15. Diabetologia. 2003 Jul;46(7):990-5 - PubMed
  16. Diabetes. 2003 Feb;52(2):573-7 - PubMed
  17. Indian J Hum Genet. 2008 May;14(2):48-54 - PubMed
  18. Biochemistry. 2000 Dec 5;39(48):14912-9 - PubMed
  19. Pharmaceuticals (Basel). 2010 Aug 1;3(8):2610-2646 - PubMed
  20. J Biol Chem. 2005 Feb 25;280(8):6441-6 - PubMed
  21. J Clin Invest. 1999 Aug;104(3):357-64 - PubMed
  22. Diabetes. 2007 Feb;56(2):531-6 - PubMed
  23. Diabetes. 2003 Oct;52(10):2630-5 - PubMed
  24. Diabetes. 1997 Apr;46(4):688-94 - PubMed
  25. Hum Biol. 2004 Feb;76(1):147-51 - PubMed
  26. Acta Diabetol Lat. 1991 Jan-Mar;28(1):91-8 - PubMed
  27. Clin Chim Acta. 1998 Jun 8;274(1):111-7 - PubMed
  28. J Clin Invest. 1994 Sep;94(3):1141-6 - PubMed
  29. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10402-6 - PubMed
  30. Diabetes. 2009 Aug;58(8):1869-78 - PubMed
  31. J Clin Endocrinol Metab. 1996 Apr;81(4):1657-9 - PubMed
  32. J Endocrinol. 2005 Jun;185(3):439-44 - PubMed
  33. Trends Biotechnol. 2004 May;22(5):253-60 - PubMed
  34. Endocr Pract. 2007 Jan-Feb;13(1):37-44 - PubMed
  35. Diabetes Care. 2004 Jun;27(6):1394-8 - PubMed
  36. J Clin Endocrinol Metab. 2000 May;85(5):2004-13 - PubMed
  37. Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):2975-80 - PubMed
  38. Hum Mol Genet. 2005 Apr 1;14(7):925-34 - PubMed
  39. Clin Chem. 1977 May;23(5):882-4 - PubMed
  40. Hum Reprod. 2005 Nov;20(11):3184-91 - PubMed
  41. Biochem Biophys Res Commun. 2009 Apr 17;381(4):496-501 - PubMed
  42. Diabetes. 2002 Oct;51(10):3135-8 - PubMed
  43. Diabet Med. 2001 Mar;18(3):206-12 - PubMed
  44. Diabetes. 1996 Jun;45(6):825-31 - PubMed
  45. Diabetes. 2001 Apr;50(4):882-5 - PubMed
  46. Diabetes. 2002 Mar;51(3):875-9 - PubMed
  47. Horm Metab Res. 2009 May;41(5):387-90 - PubMed
  48. J Clin Endocrinol Metab. 2006 Jun;91(6):2334-9 - PubMed
  49. N Engl J Med. 1971 Feb 18;284(7):353-7 - PubMed
  50. J Clin Endocrinol Metab. 2005 Jun;90(6):3629-37 - PubMed

Publication Types